LinkedIn
icn_podcast Podcasts
View All Upcoming Courses
Specialty
Course Type
Search
Login
Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login
Menu

Putting Patients First: Best Practices for Neurotrophic Keratitis Diagnosis and Treatment

By: Kelly K. Nichols, OD, MPH, PhD, FAAO; Scott Hauswirth, OD, FAAO; Walter O. Whitley, OD, MBA, FAAO

Begin Course
Webinar Credits: 1.5

This previously recorded satellite symposium features an engaging presentation on the potential causes of neurotrophic keratitis, how to differentiate it from similar diseases, and when referrals may be necessary. Treatment options will also be discussed, including the mechanisms of action of newer therapies and when they should be introduced.

Case discussions and audience question-and-answer session were also recorded. 

Expiration Date: Wednesday, November 27, 2024
Release Date: December 3, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Describe the stages of neurotrophic keratitis, and how to differentiate it from similar diseases
  • Summarize mechanisms of action of newer treatments and when they should be introduced into treatment regimens for neurotrophic keratitis
  • Identify the relationships between disease characteristics, drug, treatment frequency, visual and anatomic outcomes
  • Recognize the various potential causes of neurotrophic keratitis and when referrals may be necessary

Accreditation and Designation Statement

Credit Designation Statement

Sponsored by

Evolve Medical Education LLC (Evolve) is an approved COPE administrator.

This activity, COPE Activity Number 123006, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1.5 hours of CE. 

Course # 75785-AS
Activity  123006

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Kelly K. Nichols, OD, MPH, PhD, FAAO

Program Chair

Professor and Dean
University of Alabama at Birmingham School of Optometry
Birmingham, AL

Scott Hauswirth, OD, FAAO

Assistant Professor
University of Colorado
Anschutz Medical Campus

Aurora, CO

Walter O. Whitley, OD, MBA, FAAO

Director of Optometric Services
Virginia Eye Consultants
Norfolk, VA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Bruder, Dompé, HanAll Bio, Kala Pharmaceuticals, Novartis, Osmotica, Oyster Point Pharma, Sight Sciences, Tarsis, Thea, and Topivent. Grant/Research: Allergan,  Kala Pharmaceuticals, NIH, and Tear Science. Stock/Shareholder: Acquiom, Alcon Vision, LacriScience, and Tear Film Innovations.

Scott Hauswirth, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: BioTissue, Eyevance, Glaukos, Horizon, Kala Pharmaceuticals, NuSight Medical, Science Based Health, and Sight Sciences. Grant/Research Support: Claris Biotherapeutics, Dompé, NiCox, Ocular Therapeutix, Oyster Point Pharma, and Sylentis. Speakers List: Kala Pharmaceuticals. Shareholder: Horizon and Oyster Point Pharma.

Walter O. Whitley, OD, MBA, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie Pharmaceuticals, Alcon Vision, Allergan, Bausch + Lomb, Bio-Tissue, Bruder Healthcare, Eyevance, Glaukos, Horizon Therapeutics, Johnson & Johnson Vision, Kala Pharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Ocusoft, Oyster Point Pharma, Quidel, Regener-Eyes, RVL Pharmaceuticals, ScienceBased Health, Sun Pharmaceutical Industries, Tarsus Pharmaceuticals, TearLab, and Thea Pharmaceuticals. Speaker’s Bureau: Aerie Pharmaceuticals, Alcon Vision, Bausch + Lomb, Bio-Tissue, Eyevance, Novartis, ScienceBased Health, and Sun Pharmaceutical Industries. Share/Stockholder: Leo Lens Technology.

The Evolve staff and planners have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Dompé.

Begin Course